We found that some HBL and HCC tumor samples have high levels of HDAC1 and Sp5, suggesting that the HDAC inhibitor SAHA could be used to reduce the HDAC1-Sp5 pathway in HBL and HCC. Here, HDAC1 is linked to neoplasm.